Video Series

Focusing on the diagnosis of Alzheimer disease, the panel discusses key diagnostic criteria, testing practices, and the role of genetic testing.

B. Joy Snider, MD, PhD, discusses the benefits of early diagnosis of Alzheimer disease and how it can impact the patient journey.

Medical experts identify key stakeholders within health plans who collaborate in the decision-making process for coverage, access, and benefit design related to prescription digital therapeutics.

Paul Jeffrey, PharmD, presents the findings of a study, which investigated patient engagement and clinical outcomes associated with the use of prescription digital therapeutics (PDTs) in the treatment of substance use disorders, and discusses the need for further research to advance the efficacy and value of PDTs in this field.

The expert panel offers comprehensive insights on the patient journey for people with Alzheimer disease, highlighting symptoms, challenges, and the diagnostic process.

The panel provides an overview of genetic factors associated with Alzheimer disease and the genetic mutations that contribute to the pathophysiology of the disease.

1) A medical urologist discusses the rationale and design of the SunRISe-1 phase 2 trial, which evaluates the combination of intravesical TAR-200 and systemic cetrelimab, as well as the TAR-200 and cetrelimab monotherapy arms, in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC), focusing on key efficacy and safety endpoints.

Neal Shore, MD, FACS, discuss the key efficacy outcomes reported for nadofaragene firadenovec (ADSTILADRIN) in the phase 3 trial for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) and compare these long-term results to other bladder-preserving therapies in this population.

Panelists delve into the data and the cost-saving evidence required by payers to cover prescription digital therapeutics (PDTs), outline the decision-making process followed by payers, and share best practices observed in real-world to ensure the successful implementation of PDTs.

A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.

Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.

An expert on pulmonary arterial hypertension discusses how sotatercept might fit into current treatment paradigms and key factors that should guide clinical decision-making.

Dr Oudiz discusses clinical data that support the efficacy and safety of emerging PAH therapies and ongoing research in the treatment space.

A medical expert discusses the various types of bacteria and fungi that can grow in the lungs and sputum of bronchiectasis patients, such as Pseudomonas aeruginosa, emphasizing the importance of an individualized approach to treatment, and notes that while fungal cultures may be positive, they may not always be clinically significant.

Pamela J. McShane, MD, explains her approach to diagnosing the underlying cause of bronchiectasis, which includes identifying cystic fibrosis in older patients, and emphasizes the importance of helping patients lead a normal life while managing their condition.

Experts give their concluding thoughts on cardiovascular care and closing disparity gaps to optimize patient outcomes.

A medical professional addresses the social aspects of bronchiectasis, emphasizing patients' embarrassment due to productive coughing in public spaces like grocery stores and churches, as well as the psychological challenges of planning travel and vacations due to the unpredictability of exacerbations, which can lead to social isolation.

Robert Gabbay, MD, PhD, gives closing thoughts and advocates that continuous glucose monitors should be supplied for all insulin-dependent diabetes patients, including at initial diagnosis, to facilitate self-management and tighter control of this disease.

The panel has an in-depth discussion on improving diversity in clinical trials. They discuss ways to increase minority participation through community partnerships, including providing transportation, lodging, and other resources needed to enable participation.

Pam R. Taub, MD, FACC, FASPC, leads a discussion on implicit bias and mandated trainings for medical license renewal that help eliminate bias and address disparities.

A medical professional explores the management of bronchiectasis exacerbations, detailing the significance of sputum color, the potential for hemoptysis, and the exacerbation of comorbidities such as COPD and asthma.

Panelists discuss desired innovations in health care technology, as well as incentives to further integrate these new technologies into patient care.

Panelists discuss technological developments, including virtual visits and mobile health, and their role in improving cardiovascular care.

A professional discussion on diagnosing type 1 diabetes based on autoimmune antibodies, oral glucose tolerance test results, fasting glucose, and hemoglobin A1C levels.

Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.

Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.

Pamela J. McShane, MD, discusses the long-term outcome of patients with bronchiectasis and emphasizes the crucial role of radiographic imaging in diagnosing the disease.

A panel of experts discuss improving collaboration between health systems and managed care organizations to ensure optimal outcomes for patients with rare diseases.